With the approval of frontline pembrolizumab monotherapy for advanced NSCLC with PD-L1 of 1% or above, how do you select who gets Chemo-IO versus pembro monotherapy if PD-L1 between 1-49%?

Topics: Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University

Answer from: Medical Oncologist at Academic Institution

Most patients with PDL1 1-49% should continue to be offered chemotherapy + IO and not pembrolizumab alone.

Comments

Medical Oncologist at NYU Winthrop Hospital
I will use Pembrolizumab alone in patients with lo...

Related Questions